Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 36

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 36
---
 upon the exercise of warrants to purchase shares of our Common Stock that were converted 
 from Legacy CERo warrants in connection with the Business Combination; (ix) 306 shares of Common Stock issuable upon the exercise of warrants  
 to purchase shares of our Common Stock sold to certain investors pursuant to the First Securities Purchase Agreement; (x) 2,500 shares         
 of Common Stock issuable upon the exercise of warrants to purchase shares of our Series A Preferred Stock sold to certain investors pursuant   
 to the First and Second Securities Purchase Agreement and conversion of the underlying shares of Series A Preferred Stock into Common          
 Stock and (xi) 221 shares of Common Stock issuable upon the exercise of Private Placement Warrants to purchase shares of our Common Stock,     
 at an exercise price of $23,000.00 per share, that were originally sold in a private placement concurrently with the Initial Public Offering;  
 and (2) the issuance by us of up to 4,375 shares of Common Stock issuable upon the exercise of public warrants to purchase shares of our       
 Common Stock, at an exercise price of $23,000.00 per share, that were originally issued in the Initial Public Offering;                        |

| ● | a registration statement with the SEC for purposes of registering of the resale from time to time of up to 319,282 shares of Common Stock, which consists of (i) 28,835 shares of Common Stock issuable upon the conversion of shares of our Series A Preferred Stock purchased by certain investors pursuant to the First Securities Purchase Agreement; (ii) 4,591 shares of Common Stock issuable upon the conversion of shares of our Series B Preferred Stock purchased by certain investors pursuant to the Second Securities Purchase Agreement; (iii) 35,370 shares of Common Stock issued upon the conversion of shares of our Series A Preferred Stock and Series B Preferred Stock; (iv) 218,342 shares of Common Stock issuable upon the conversion of 300% of the number of outstanding shares of our Series C Preferred Stock purchased by certain investors pursuant to the Third Securities Purchase Agreement; (v) 125 shares of Common Stock issued to a stockholder in a reallocation of shares in connection with the consummation of the Business Combination; (vi) 4,088 shares of Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock, at an exercise price of $196.00 per share, which warrants were sold to certain investors pursuant to the Third Securities Purchase Agreement (the “Series C